This document is a regulatory filing submitted to the BSE and NSE pursuant to SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations, 30 and 51. It transmits an investor presentation detailing the company's un-audited financial results for the quarter ended June 30, 2026 (Q1 FY27).

Financial Performance Highlights (Consolidated)

Profit & Loss Statement (₹ millions):

  • Income from Operations (Net): ₹6,776.4 in Q1 FY27 vs. ₹7,080.5 in Q1 FY26, a decrease of 4.3% Year-on-Year (YoY).
  • Cost of Goods Sold (COGS): ₹1,142.3 in Q1 FY27 vs. ₹980.9 in Q1 FY26, an increase of 16.5% YoY.
  • Employee Expenses: ₹3,891.0 in Q1 FY27 vs. ₹3,519.0 in Q1 FY26, an increase of 10.6% YoY.
  • Other Expenses: ₹1,142.3 in Q1 FY27 vs. ₹1,173.8 in Q1 FY26, a decrease of 2.7% YoY.
  • EBITDA: ₹600.8 in Q1 FY27 vs. ₹1,406.8 in Q1 FY26, a decrease of 57.3% YoY.
  • EBITDA Margin %: 8.9% in Q1 FY27 vs. 19.9% in Q1 FY26.
  • Other Income: ₹181.6 in Q1 FY27 vs. ₹247.5 in Q1 FY26, a decrease of 26.6% YoY.
  • Depreciation & Amortization: ₹906.8 in Q1 FY27 vs. ₹813.5 in Q1 FY26, an increase of 11.5% YoY.
  • Finance Cost (Incl. Forex Impact): ₹370.9 in Q1 FY27 vs. ₹427.6 in Q1 FY26, a decrease of 13.3% YoY.
  • Exceptional Items: (₹16.9) in Q1 FY27 vs. (₹26.5) in Q1 FY26, a decrease of 36.2% YoY.
  • Profit Before Tax (PBT): (₹512.2) loss in Q1 FY27 vs. ₹386.7 profit in Q1 FY26, a decrease of 232.5% YoY.
  • Tax Expense: ₹66.6 in Q1 FY27 vs. ₹152.6 in Q1 FY26.
  • Profit After Tax (PAT): (₹578.8) loss in Q1 FY27 vs. ₹234.1 profit in Q1 FY26, a decrease of 347.2% YoY.
  • PAT Margin %: -8.5% in Q1 FY27 vs. 3.3% in Q1 FY26.

Segment-Wise Performance

EBITDA Margin % by Segment:

| Segment | Q1 FY27 | Q1 FY26 | FY26 | FY25 |

| CDMO | 6.3% | 17.9% | 19.4% | 18.9% |

| Marketable Molecules | 18.6% | 32.4% | 18.8% | 9.4% |

Management Commentary on Results

  • The 4.29% YoY decline in net revenue was primarily driven by a deferment of CDMO revenue, partly offset by growth in the Marketable Molecules (MM) segment.
  • CDMO Revenue: Declined by 12.6% YoY. This was due to a customer-requested rescheduling of project deliverables worth approximately CHF 10 million to the second half of the financial year.
  • Marketable Molecules (MM) Revenue: Increased by 48% in Q1 FY27 compared to Q1 FY26, primarily driven by higher Cholesterol revenue.
  • The significant decline in overall EBITDA margin was attributed to:
  • The deferment of high-margin CDMO revenues against a largely fixed cost base.
  • A notional foreign exchange loss of INR 117.3 million impacting margins.
  • The decline in MM segment margin to 18.6% from 32.4% YoY was primarily driven by a higher sales mix of Cholesterol compared to higher-margin Vitamin D Analogues. The company noted these Q1 FY27 margins are in line with full-year FY26 margins.

Capital Expenditure and Debt Position

  • Capex: Addition during Q1 FY27 was CHF 4.9 million.
  • Net Debt: Net debt excluding lease liabilities stood at CHF 153.6 million as of June 30, 2026, compared to CHF 146.8 million as of March 31, 2026. The closing CHF/INR exchange rate was used for this calculation.

Corporate and Regulatory Information

  • The enclosed investor presentation was also being hosted on the company's website, www.imdcal.com, in accordance with SEBI LODR Regulations 46 and 62.
  • The document includes a standard Safe Harbor Statement regarding forward-looking statements.
  • The company describes itself as a fully integrated global CDMO (Contract Development and Manufacturing Organisation) with capabilities from process R&D to commercial manufacturing of APIs. It has a presence in India, Switzerland, UK, France, China, and the Netherlands.
  • Key strengths highlighted include its bi-continental manufacturing footprint, end-to-end capabilities, and expertise in areas like ADC & Bioconjugation.